key: cord-0701820-4a2qftpf authors: Lazarus, Gilbert; Audrey, Jessica; Kharisma Wangsaputra, Vincent; Tamara, Alice; Tahapary, Dicky L. title: High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis date: 2020-12-09 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2020.108561 sha: e86d1edc11dd72c3c9a669869988c26493086e0e doc_id: 701820 cord_uid: 4a2qftpf Aims To investigate the prognostic value of admission blood glucose (BG) in predicting COVID-19 outcomes, including poor composite outcomes (mortality/severity), mortality, and severity. Methods Eligible studies evaluating the association between admission fasting BG (FBG) and random BG (RBG) levels with COVID-19 outcomes were included and assessed for risk of bias with the Quality in Prognosis Studies tool. Random-effects dose-response meta-analysis was conducted to investigate potential linear or non-linear exposure-response gradient. Results The search yielded 35 studies involving a total of 14,502 patients. We discovered independent association between admission FBG and poor COVID-19 prognosis. Furthermore, we demonstrated non-linear relationship between admission FBG and severity (Pnon-linearity<0.001), where each 1 mmol/L increase augmented the risk of severity by 33% (risk ratio 1.33 [95% CI: 1.26-1.40]). Albeit exhibiting similar trends, study scarcity limited the evidence strength on the independent prognostic value of admission RBG. GRADE assessment yielded high-quality evidence for the association between admission FBG and COVID-19 severity, and moderate-quality evidence for its association with mortality and poor outcomes. Conclusion High admission FBG level independently predicted poor COVID-19 prognosis. Further research to confirm the prognostic value of admission RBG and to ascertain the estimated dose-response risk between admission FBG and COVID-19 severity are required. The rapidly spreading coronavirus disease 2019 (COVID- 19) pandemic has placed significant burdens on healthcare systems worldwide, with millions of cases and hundredthousands of deaths. [1] This is further aggravated by the fact that COVID-19 patients are at risk of rapid health deteriorations leading to multiorgan failure and death [2] , indicating that early and reliable indicators to enable risk stratifications are urgently needed to help clinicians anticipate and promptly treat these patients. Furthermore, these indicators may also contribute to the attainment of efficient resource allocation, which is severely limited during this pandemic. [3] In light of this, recent reports have shown that that high admission blood glucose (BG) may yield prognostic values in predicting poor COVID-19 outcomes. [4, 5] Nevertheless, robust risk quantification of poor COVID-19 outcomes across wide array of admission BG levels has yet to be well-established. Furthermore, some studies have argued that the prognostic value of admission BG level is primarily driven by diabetes [6, 7] , while some others stated that the effect may be independent of diabetes history [8, 9] , thus emphasizing the need to establish a firm evidence on the current premises. Therefore, this review intends to summarize the current knowledge regarding the role of admission BG level in determining the prognosis of COVID-19 patients, thus contributing to risk stratification and patient management in clinical settings. This systematic review was conducted in accordance with the guideline recommended by the Cochrane Prognosis Methods Group [10] and reported based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [11] . A detailed protocol has been previously registered in PROSPERO (CRD42020154772 [12] ). Two independent investigators performed thorough literature searches, with discrepancies resolved by a third investigator in a blinded fashion. We initially searched PubMed, EMBASE Table S1 . Then, we additionally searched gray literature (viz, Google Scholar and ProQuest), preprint (via, MedRxiv and BioRxiv), and the World Health Organization (WHO) COVID-19 research databases, in addition to manually hand-searching reference lists from included studies and similar reviews. Lastly, we collected the PubMed ID of each included studies and ran additional search using the PubMed's 'similar articles' algorithm. Subsequently, the retrieved results were deduplicated and screened against the pre-specified eligibility criteria. Inclusion criteria were set to filter primary studies investigating the association between admission BG level and poor outcomes among COVID-19 patients (see Appendix Table S2 ). Admission BG level was determined from the first BG measurement following patients' admission to hospital prior to any intervention, while poor outcomes were further dichotomized into mortality and severity. [13] Conversely, studies were excluded if any of the following criteria were met: (1) case reports, case series, or letter to editors; (2) irretrievable full-text articles; or (3) non-English articles. Data extraction and risk of bias assessment were performed by two independent reviewers using a pre-specified form, with discrepancies resolved by the consensus with an independent third investigator. Details on data items and handling are further discussed in Appendix pg. 7. The main outcomes in this review were the risk of poor outcome, mortality, and severity among COVID-19 patients. Poor outcome was defined as composite outcome of death or severity. However, in studies which reported only mortality or severity outcome, we would still separately analyze each outcome rather than pooling them into poor outcome to avoid model selection bias. Whenever available, outcomes on severity were further analyzed per following criterion: invasive ventilation, intensive care unit (ICU) admission, acute respiratory distress syndrome (ARDS), and shock [14] . Included studies were further assessed for methodological quality by using the Quality in Prognosis Studies tool [15] and subsequently judged to be yielding low, moderate, or high risk of bias (Appendix Table S3 ). Lastly, the certainty of the evidence was evaluated using the modified Grading of Recommendations Assessment, Development, and for each included study. The interval length of the highest open-ended category was assumed to be 1.5 times the width of the adjacent category; while the lower limit of the open-ended lowest category was estimated to be 3.9 mmol/L. [20] Then, study-specific linear trend was estimated using the generalized least squares method and pooled using the two-stage random effects metaanalysis. Meanwhile, potential non-linear dose-response trend was evaluated using restricted cubic splines with three-knots model at the 10 th , 50 th , and 90 th percentiles, and subsequently pooled using the restricted maximum likelihood method in a multivariate random-effects metaanalysis. The Wald test was used to assess for non-linearity. A priori, we determined subgroup and sensitivity analyses only for adjusted results. The details on the literature search process are summarized on Figure 1 . Table S4 ). In quantitative analysis, 10 studies were excluded as seven [21] [22] [23] [24] [25] [26] [27] only reported Pvalue and three [28] [29] [30] reported different effect measures. Figure S1 ), which may partly be explained by the fact that all but two studies [24, 31] were conducted retrospectively. The summary of adjusted and unadjusted pooled effects of high vs low meta-analysis are consecutively listed in Table 1 and Appendix Table S5 ; and the certainty of evidence as assessed with the GRADE approach is summarized in Appendix Table S6 . GRADE assessments of the prognostic value of FBG resulted in high-quality evidence for severity and moderate-quality evidence for mortality and poor outcome, whereas the remaining domains yielded very low-to-low-quality evidence. Overlapping populations were observed in four studies [32] [33] [34] [35] (Appendix Table S7 ), and analyses were prioritized to Wang et al. [32] due to larger sample size. We demonstrated that FBG was independently associated with poor prognosis in COVID-19 patients ( Table 1 and Figure 3A -C), although all models yielded substantial heterogeneity (I 2 =84% for poor outcome; I 2 =87% for mortality, I 2 =69% for severity; all with P heterogeneity <0.01). Subgroup analyses based on study design and location were not possible as all studies included in the meta-analysis were retrospective and conducted in China. Furthermore, publication bias assessment was only eligible for mortality outcome. We discovered that high admission FBG increased the risk of poor outcomes by 20% (RR 1.20 [95% CI: 1.04-1.39]; Figure 3A ). However, we were unable to establish firm evidence as the observed heterogeneity remained unexplained (see footnote in Table 1 ) and the observed effects were diminished following the exclusion of Fadini et al. [36] or Li et al. [35] (Appendix Figure S2A ). In DRMA comprising of two studies [36, 37] , we failed to observe exposureresponse gradient (RR 1.23 [95% CI: 0.90-1.68]; P heterogeneity =0.008; Figure 4A ), although studyspecific slopes indicated that such trend exists. Considering this, we deemed the quality of evidence to be moderate for qualitative assessment and low for quantitative assessment. For outcomes on mortality, we found a relatively consistent result (RR 1.81 [95% CI: 1.41-2.33]; Figure 3B ); although the observed heterogeneity remained unexplained following subgroup analysis, except when the analysis was stratified according to the number of category (i.e. I 2 =2% for studies reporting two categories). Furthermore, we discovered that the smallersized studies yielded excessively wide CIs as compared to larger studies (Table 1) . Nonetheless, sensitivity analysis suggested that these small studies did not contribute much to the pooled estimate as our findings remained consistent, except when Fadini et al. [36] or Chang et al. [38] were excluded, which exaggerated the pooled estimates (Appendix Figure S2B) . We detected asymmetry in the funnel plot which was further ascertained by Egger's test (P<0.001; Appendix Figure S3 ), although Begg's test indicated otherwise (P=0.245), suggesting the presence of publication bias. Nevertheless, we did not downgrade the outcome for publication bias upon qualitative assessment as most studies adequately adjusted for potential confounders (Appendix Table S8 ). DRMA for mortality outcome included three studies [32, 36, 37] as overlapping populations were detected in two studies [32, 35] . We were also unable to observe any exposure-response gradients although most studies reported otherwise [32, 35, 37] . However, when analysis was conducted only for non-diabetic patients, we observed an elevated mortality risk of about 38% per 1 mmol/L increase (RR 1.38 [95% CI: 1.21-1.57]; Appendix Figure S4 ). Despite this, we decided to upgrade the certainty of evidence for exposure-response gradient only for qualitative summary, resulting in the judgment of evidence quality for qualitative and quantitative analysis to be moderate and very low, respectively. This implied that we were confident that admission FBG was independently associated with mortality in COVID-19 patients, but the interpretation of the pooled estimate should be made with caution. Non-linear DRMA for poor outcome and mortality were not conducted since only one study reported three or more categories for each outcome. [32, 37] With regards to outcomes on severity, we revealed that high admission FBG level increased the patient's risk of developing severe COVID-19 infection by more than two-folds Figure 4B ) across the range between 4.5 mmol/L and 14.1 mmol/L. Moreover, we observed a non-linear relationship (P non-linearity <0.001), where the risks of progression to severe COVID-19 cases decelerated starting from 6.6 mmol/L and re-exponentiated starting from admission FBG level of 8.1 mmol/L ( Figure 4C ). Both linear and non-linear trends remained consistent following sensitivity analyses (Appendix Table S8 and Figure S5 ). When dose-response analysis was conducted only for non-diabetic patients, we observed a slightly higher risk with a RR of 1. . Furthermore, diabetes-stratified analyses for mortality and severity outcomes revealed that the observed trends were non-significant for diabetic subgroup, whereas the models for non-diabetic subgroups remained robust (Table 1) . Due to the paucity of studies reporting specific criteria of COVID-19 severity (i.e. ICU admission, invasive ventilation, ARDS, shock), we were unable to ascertain the independent effects to the respective outcomes. Nonetheless, the results were coherent to the main outcomes as the pooled unadjusted effects showed similar trends in predicting ICU admission, invasive ventilation, ARDS, and shock (Appendix Table S5 ). However, as our findings were limited, we judged the certainty of evidence to be low for ICU admission and invasive ventilation, and very low for ARDS and shock (Appendix Table S6 ). Similar to FBG, we discovered that COVID-19 patients with high RBG level at admission were more susceptible to poor prognosis (Appendix Table S5 ). Nevertheless, we were unable to establish a strong evidence on the independent prognostic value of admission RBG due to paucity of studies and equivocal trends. High vs low meta-analysis for adjusted effects was only eligible for outcomes on ICU admission, which resulted in non-significant estimate (RR 1.25 [95% CI: 0.84-1.84]; Figure 4D ), although study-specific estimates suggested otherwise. Considering this, we judged the quality of evidence to be low for mortality, and very low for the remaining outcomes (Appendix Table S6 ). With regards to mortality, we found that the prognostic value of admission RBG was independent of age and sex. [28, 41] [41] Subgroup and sensitivity analyses, as well as publication bias assessment and DRMA was not conducted due to insufficient number of studies. This meta-analysis showed that high admission BG level was associated with poor prognosis in COVID-19 patients. Although we were unable to establish a firm evidence on the independent prognostic value of admission RBG, our results on admission FBG level were consistent and robust. Furthermore, we also demonstrated exposure-response gradient between admission FBG level and COVID-19 severity. Although the potential non-linear association between admission FBG level with poor composite and mortality outcomes remained unexplored due to paucity of studies, we were able to establish non-linear relationship between admission FBG level and severity. However, in contrast with Zhu et al. [34] , we did not observe a J-shaped association between admission FBG and COVID-19 severity, which may be explained by the fact that all but one study [34] reported only three categories. Despite this, our findings were in accordance with a study by Alahmad et al. [44] which stated that the association between admission FBG and ICU admission was logarithmic, thus further corroborating our premises. Further analysis indicated that the observed effects were more accentuated in patients without prior history of diabetes; which was intriguing, considering the fact that there was as increasing proportion of COVID-19 patients presenting with hyperglycemia despite having no prior diabetic history. [32, 36, 45] Furthermore, our findings indicated that at-admission hyperglycemia was associated with poorer outcomes regardless of prior diabetes status, suggesting the existence of a more direct link between glycemic status and poor COVID-19 outcomes. The relationship between COVID-19 severity and hyperglycemia is possibly bidirectional, wherein infection might bring about state of stress and trigger an enhanced release of proinflammatory cytokines which may lead to insulin resistance. [46] Stress may also induce the release of stress hormones which trigger liver glycogenolysis, aggravating the effects. [47] Furthermore, SARS-CoV-2 is known to bind to angiotensin-converting enzyme 2 (ACE2) receptors, which are found to be expressed in pancreatic beta-cells, thus rendering it a target for the viral attack. Such binding provides a route for the virus to enter and damage the pancreatic islets, resulting in a defect of insulin production, as indicated in previous study with its SARS virus counterpart. [48] Together, these factors may contribute to the development of acute hyperglycemia in COVID-19 patients. The mechanism by which acute hyperglycemia drives the progression of COVID-19 remains largely unexplored. A study by Fadini et al. found that a decline in respiratory parameters was most responsible for mediating the effects of hyperglycemia on the outcome. [36] Diabetes and hyperglycemia were previously known to induce structural changes in the lungs, giving rise to pulmonary remodelling and the subsequent restrictive respiratory pattern. [49] Moreover, hyperglycemia is also known to generate reactive oxygen species and induces oxidative stress [46] , leading to endothelial dysfunction which may cause further hyperglycemic pulmonary microangiopathy. [50] This is in line with the findings of a study by Lampasona et al. which demonstrated that inflammation and coagulopathy, rather than impaired antibody response as such present in individuals with diabetes, were more responsible in aggravating the outcomes. [51] Therefore, this explains the poorer prognosis found in hyperglycemic patients without prior diabetic history, and again supporting the direct link between glucose level and disease progression. Altogether, these findings illustrate the potential utility of admission BG as a predictor for poor prognosis in COVID-19 patients. Considering that BG measurement is relatively practical and instant, its quantification upon admission would be beneficial in predicting the likelihood of progression to severe COVID-19 cases. Therefore, we encourage clinicians to routinely obtain FBG values of each COVID-19 suspected case at admission, thus providing a simple method of risk stratification for management of patients in clinical settings, which would be particularly helpful in streamlining the limited number of medical resources during the current pandemic. Although our findings also favored the use of admission RBG, future research are required as we were unable to comprehensively explore the independent prognostic value of admission RBG due to paucity of studies. Furthermore, the current evidence indicated that the cut-off values to predict poor prognosis in COVID-19 patients are still equivocal [38, 41, 52, 53] , suggesting that future large multicenter studies are required to obtain the most optimum cut-off value. Despite the fact that our findings supported the prognostic value of high admission BG, the unexplained heterogeneity we observed along with the fact that all studies included in the quantitative analysis were retrospective and conducted in China may limit the generalizability of our findings. Furthermore, most of the studies included in the DRMA on severity outcome yielded moderate risk of bias, thus indicating potential overestimation of the observed effects due to imprecision. These indicated that the observed effects should be interpreted cautiously, and future studies with higher quality of evidence are required to confirm the estimated risks. Nonetheless, our results were consistent with the independent prognostic value of admission FBG, thus we judged the certainty of evidence for severity to be high, and for mortality and poor outcome to be moderate. To the best of our knowledge, this is the first meta-analysis conducted to show the potential use of admission BG as a predictor of poor prognosis in COVID-19 patients. Although our eligibility criteria may introduce language bias, our study included a relatively large number of cohorts and only four non-English articles were excluded [54] [55] [56] [57] , suggesting that any potential bias was negligible. We hope that our findings may enhance the current knowledge on the management of COVID-19, thus contributing to the alleviation of the devastating disease burden. In conclusion, this meta-analysis adds to the growing body of evidence corroborating the potential utility of admission BG as a predictor of poor prognosis in COVID-19 patients. There is a high-quality evidence on the prognostic value of admission FBG towards severity, and moderate-quality evidence on its prognostic value towards mortality and poor outcome, while the other outcomes yielded very low-to-low quality evidence. In addition, we demonstrated non- The authors declare no conflict of interest. This project received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The data that supports the findings of this study are available in the supplementary material of this article. 0.008 † Subgroup analyses to explore potential source of heterogeneity was not possible as no subgroup yielded a minimum of two studies. ‡ Subgroup analysis based on study design and location were not possible as all included studies were retrospective and conducted in China. § Overlapping populations were observed between Li et al. [35] , Wang et al. [32] , Zhang et al. [33] , and Zhu et al. [34] , of which Wang et al. [32] was prioritized for analysis due to larger sample size. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics Biomarkers associated with COVID-19 disease progression Effects of Hyperglycaemia on Complications of COVID-19: A Meta-Analysis of Observational Studies At-admission hyperglycemia is consistently associated with poor prognosis and early intervention can improve outcomes in patients with COVID-19 Is diabetes mellitus a risk factor for COronaVIrus Disease 19 (COVID-19)? Diabetes and COVID-19: A systematic review on the current evidences Hyperglycemia and COVID-19: What was known and what is really new? Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19 A guide to systematic review and meta-analysis of prognostic factor studies Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement Admission blood glucose level as a prognostic factor for COVID-19 severity and mortality: a systematic review World Health Organization. Clinical management of COVID-19 -Interim guidance 27 Clinical management of severe acute respiratory infection when COVID-19 is suspected (v1.2) Evaluation of the quality of prognosis studies in systematic reviews Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease Methodology for dealing with duplicate study effects in a meta-analysis Measuring inconsistency in metaanalyses Blood glucose concentration and risk of pancreatic cancer: Systematic review and dose-response meta-analysis Higher Comorbidities and Early Death is Characteristic of Hospitalized African-American Patients with COVID-19 Clinical findings of patients with coronavirus disease Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19 Clinical characteristics and outcomes of patients with severe covid-19 with diabetes Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study Factors Associated with Early Invasive Ventilation in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes A Risk Score to Predict Admission to Intensive Care Unit in Patients With COVID-19: The ABC-GOALS Score Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study Correlation between Fasting Blood Glucose Level at Admission and Mortality in COVID-19 Patients: A Retrospective Study Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19 Newlydiagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study Hyperglycemia is a strong predictor of poor prognosis in COVID-19 J-shaped Association Between Fasting Blood Glucose Levels and COVID-19 Severity in Patients without Diabetes Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study Higher fasting plasma glucose reduced the survival rate of 306 hospitalized patients with COVID-19 in Wuhan Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Fasting blood glucose and COVID-19 severity: Nonlinearity matters. Diabetes Care 2020:dc201941 Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study Stress-hyperglycemia, insulin and immunomodulation in sepsis COVID-19 and diabetes : a review literature 2020 Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes The diabetic lung: an easy target for SARS-CoV-2? Diabetic microvascular disease and pulmonary fibrosis: The contribution of platelets and systemic inflammation Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study Risk factors influencing the prognosis of elderly patients infected with COVID-19: a clinical retrospective study in Wuhan Admission biochemical test associated with the prognosis of COVID-19: a multi-centered retrospective cohort study Logistic regression analysis of death risk factors of patients with severe and critical coronavirus disease Relation Between Blood Glucose and the Prognosis of Severe Coronavirus Disease 2019 / 血糖与重型2019冠状病毒病预后的关系. 中南大学学报(医学版) 2020 Analysis of influencing factors of death in patients with COVID-19 / 新型冠状病毒肺炎患者死亡影响因素分析